LegoChem Biosciences
LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $415m Valuation: $1.6b | Acquisition | |
| Total Funding | 000k | ||
Related Content
LegoChem Biosciences specializes in the development of innovative antibody-drug conjugates (ADCs) and small molecule-based drugs, targeting therapeutic areas such as antibiotics, anti-fibrotic, and immuno-oncology. The company leverages its proprietary platform technologies, ConjuAll, to design ADCs with improved efficacy, safety, and tolerability compared to existing ADC drugs. Serving the pharmaceutical and biotechnology sectors, LegoChem Biosciences operates in the global healthcare market, focusing on early-stage drug discovery and development. The business model revolves around research and development, licensing agreements, and partnerships with larger pharmaceutical companies. Revenue is generated through milestone payments, royalties, and licensing fees.
Keywords: antibody-drug conjugates, ADCs, immuno-oncology, antibiotics, anti-fibrotic, ConjuAll, drug discovery, biotechnology, pharmaceutical, proprietary platform.
